Results 71 to 80 of about 3,203 (180)

Effects of enalapril and paricalcitol treatment on diabetic nephropathy and renal expressions of TNF-α, p53, caspase-3 and Bcl-2 in STZ-induced diabetic rats.

PLoS ONE, 2019
This study aimed to assess the renopreventive effect of enalapril and/or paricalcitol on streptozotocin (STZ) diabetes-induced nephropathy and to elucidate their mechanisms of action through investigation of the effects on renal oxidative stress ...
Osama M Ahmed, Tarek M Ali, Mohamed A Abdel Gaid, Ahmed A Elberry   +3 more
doaj   +1 more source

Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size

, 2011
Paricalcitol is more effective than calcitriol in hemodialysis patients (HD) with secondary hyperparathyroidism (SHPT), but it is not effective in some of them.
Maresca, Giulia, Panocchia N, Enrico DISTASIO, Carlo VULPIO, Giovanna LUCIANI, Vulpio C, Vulpio, Carlo, Silvia CACACI, Nicola PANOCCHIA, Maresca, Gian Marco, Cacaci, Silvia, Panocchia, Nicola, Di Stasio E, Giulia MARESCA, Maurizio BOSSOLA, Bossola, Maurizio, Bossola M, Luciani, Giovanna   +17 more
core   +1 more source

Effectiveness of treatment with oral paricalcitol in patients on peritoneal dialysis: a Spanish multicenter study

, 2013
[Abstract] Aims: Recently, oral form of paricalcitol has allowed extension of treatment to ambulatory patients on peritoneal dialysis but few data have been published about the benefits of paricalcitol in this subgroup.
Bajo, Auxiliadora, Sánchez, Emilio, Ramos, Rosa, Barbosa, Francesc, Borràs, Mercè, González, Teresa, Pérez-Fontán, Miguel   +6 more
core   +1 more source

Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: A US perspective

, 2009
Objective: The objective of this study was to determine the cost effectiveness of paricalcitol versus calcitriol for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease in the United States setting.
Andress, D.L. (Dennis), Sterz, R. (Raimund), Marx, S.E. (Steven), Nuijten, M.J.C. (Mark)   +3 more
core   +1 more source

Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study

, 2017
In stable renal transplant recipients with hyperparathyroidism, previous studies have indicated that vitamin D agonist treatment might have anti-proteinuric effects. Animal studies indicate possible anti-fibrotic and anti-inflammatory effects.
Junbai Wang, Geir Mjøen, Hartmann, Anders, Hallvard Holdaas, My Hanna Sofia Svensson, Svensson, My Hanna Sofia, Pihlstrøm, Hege, Kasprzycka, Monika, Hammarström, Clara Louise, Gatti, Francesca, Karsten Midtvedt, Eide, Ivar Anders, Haraldsen, Guttorm, Wang, Junbai, Dahle, Dag Olav, Franscesca Gatti, Monika Kasprzycka, Mjøen, Geir, Holdaas, Hallvard, Hege Kampen Pihlstrøm, Midtvedt, Karsten, Guttorm Haraldsen, Dag Olav Dahle, Anders Hartmann, Clara Hammarström, Ivar Anders Eide   +25 more
core   +1 more source

Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study

International Journal of Nephrology and Renovascular Disease, 2014
Daniela Paola Roggeri,1 Mario Cozzolino,2 Sandro Mazzaferro,3 Diego Brancaccio,4 Ernesto Paoletti,5 Alessandro Roggeri,1 Anna Maria Costanzo,6 Umberto di Luzio Paparatti,6 Vincenzo Festa,6 Piergiorgio Messa7 1ProCure Solutions, Nembro, Bergamo ...
Roggeri DP, Cozzolino M, Mazzaferro S, Brancaccio D, Paoletti E, Roggeri A, Costanzo AM, di Luzio Paparatti U, Festa V, Messa P   +9 more
doaj  

The role of D2 vitamin metabolite paricalcitol in nephroprotective strategy in chronic disease of the kidneys

Терапевтический архив, 2011
Calcitriol is important in nephroprotective strategy in chronic disease of the kidneys (CDK). However, its long-term use often results in hypercalciemia with metastatic calcification. Compared to calcitriol, paricalcitol (zemplar) - metabolite of vitamin
Yuriy Sergeevich Milovanov, Lidiya Vladimirovna Kozlovskaya, Lyudmila Yur'evna Milovanova, Yu S Milovanov, L V Kozlovskaya, L Yu Milovanova   +5 more
doaj  

Experience with active vitamin D metabolites in phosphorus-calcium metabolic disorders in patients with predialysis chronic kidney disease

Терапевтический архив, 2014
AIM: To evaluate the efficacy and safety of alfacalcidol and paracalcitol used to correct impaired phosphorus-calcium metabolism (PCM) in patients with predialysis chronic kidney disease (CKD)/MATERIAL AND METHODS: Examinations were made in 128 patients ...
L Iu Milovanova, I A Dobrosmyslov, Iu S Milovanov   +2 more
doaj  

Paricalcitol therapy: practical experience

Public Health, Economy and Management in Medicine
Mineral bone disease in chronic kidney disease is associated with increased morbidity, decreased quality of life, and heightened mortality. Paricalcitol is potentially able to reduce such complications. There were examined 20 chronically dialyzed patients (9 women and 11 men) with PTH values > 85 pmol/l (> 800 pg/ml) (normal values: 10-85 pg/ml ...
openaire   +1 more source

Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial

, 2018
Postkidney transplant hyperparathyroidism is a significant problem. Vitamin D receptor agonists are known to suppress parathyroid hormone (PTH) secretion.
Kremers, W. K., Larson, T. S., Stegall, M. D., Cosio, F. G., Hamawi, K., Park, W. D., Kumar, R., Amer, H., Heilman, R. L., Mazur, M. J., Griffin, M. D.   +10 more
core